Abstract | OBJECTIVES: METHODS: Under ultrasound guidance, the first cohort of dams received an intra-amniotic injection of the alarmin high-mobility group box-1 ( HMGB1, n=10) or phosphate-buffered saline (PBS, n=9) as controls. A second cohort of dams received HMGB1 intra-amniotically and were subcutaneously treated with betamethasone (n=15) or vehicle (n=15). Dams were observed until delivery, and perinatal outcomes were observed. RESULTS: Intra-amniotic HMGB1 reduced gestational length (p=0.04), inducing preterm birth in 40% (4/10) of cases, of which 100% (4/4) were categorized as late preterm births. Importantly, treatment with betamethasone extended the gestational length (p=0.02), thereby reducing the rate of preterm birth by 26.6% (from 33.3% [5/15] to 6.7% [1/15]). Treatment with betamethasone did not worsen the rate of neonatal mortality induced by HMGB1 or alter weight gain in the first three weeks of life. CONCLUSIONS:
|
Authors | Jose Galaz, Roberto Romero, Marcia Arenas-Hernandez, Bogdan Panaitescu, Robert Para, Nardhy Gomez-Lopez |
Journal | Journal of perinatal medicine
(J Perinat Med)
Vol. 49
Issue 7
Pg. 897-906
(Sep 27 2021)
ISSN: 1619-3997 [Electronic] Germany |
PMID | 33878254
(Publication Type: Journal Article)
|
Copyright | © 2021 Walter de Gruyter GmbH, Berlin/Boston. |
Chemical References |
- Alarmins
- Anti-Inflammatory Agents
- HMGB1 Protein
- Betamethasone
|
Topics |
- Alarmins
- Animals
- Anti-Inflammatory Agents
(therapeutic use)
- Betamethasone
(therapeutic use)
- Chorioamnionitis
(chemically induced, physiopathology)
- Female
- HMGB1 Protein
- Injections, Subcutaneous
- Kaplan-Meier Estimate
- Mice
- Mice, Inbred C57BL
- Pregnancy
- Premature Birth
(etiology, prevention & control)
- Treatment Outcome
|